IL6 and obesity due to melanocortin 4 receptor deficiency: Since the observed changes could partially be attributed to TNF-α and IL-6 activity, an anti-inflammatory therapy might be a promising early therapeutic prevention option, especially in high-risk patients, such as those suffering from obesity or T2DM.